Rani Therapeutics reports positive preclinical safety data for RaniPill capsule in 60-day GLP study

Rani Therapeutics Holdings, Inc.

60-day repeat administration in healthy animals showed no treatment-related adverse events; all animals remained healthy.
Study evaluated RT-100 (RaniPill with mannitol) vs. mock capsule; supports safety for clinical trials.
Data enable launch of longer-term trials including Phase II study of RT-102 for osteoporosis planned for 2023.
RaniPill platform is drug-agnostic, aiming to replace injections for biologics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.